NUVALENT INC-A

Nuvalent insider buys signal confidence in GSK deal and growth potential – a structured Rule 10b5‑1 plan that boosts investor trust and may lift the stock.

Nuvalent CEO’s latest 30k‑share buy signals strong confidence after the $10.6 B GSK deal, suggesting the stock may still have upside in its oncology pipeline.